GLYCOGEN SYNTHASE KINASE-3 BETA PROTEIN INHIBITION BY SELECTED PHYTOCOMPOUNDS IN SILICO

  • Vanitha Varadharaj Vels University, Chennai
  • Naresh Kandakatl

Abstract

Objectives: Bioactive phytocompounds are a rich source of chemopreventive substance. In the present investigation, docking study was performed for the selected bioactive phytocompounds such as oleanolic acid, ecdysterone, betaine, stigmasterol acetate, and cinnamic acid to evaluate their affinity to glycogen synthase kinase-3 beta (GSK-3β) protein, a wound-healing biomarker. 2-chloro-5-[4-(3-chloro-phenyl)-2, 5-dioxo-2,5-dihydro-1h- pyrrol-3-ylamino]-benzoic acid was used as an inhibitor for GSK-3β with minimum binding energy (−31.5 kcal/mol).

Methods: Molecular docking study was conducted using AutoDock 4.2 version and the visualization result using Discover Studio 4.5.

Results: The docking analysis ranked the selected phytocompounds that have high theoretical scores to bind to the proteins. The binding mode of the phytocompounds that bound to all the target proteins with high affinity was studied. The simulation demonstrated that the protein-ligand complex stabilized by multiple hydrogen bonds (H-bonds) was preferentially formed at the catalytic site. The results highlighted in this study reveals that among the selected lead phytocompounds that docked into the active site of GSK-3β, ecdysterone showed acceptable 6 H-bond interactions with residues LYS85, TYR134, ARG141, GLN185, ASP200, PRO136 when compared to the reference compound with 5 H-bond interactions.

Conclusion: Thus, based on the docking score ecdysterone could be considered as a novel compounds that can be used for experimental studies for the inhibition of GSK-3β kinase. These results can be helpful for further design of novel GSK-3β inhibitors.

Keywords: Phytocompounds, Molecular docking, Simulation, Receptor, Ligand, Inhibition.

References

1.Newman DJ, Cragg GM, Snader KM. The influence of natural products upon drug discovery. Nat Prod Rep2000;17(3):215-34.
2.Buss AD, Cox B, Waigh RD. Drug discovery. In: Abraham DJ, editor. Burger’s Medicinal Chemistry and Drug Discovery. 6th ed., Vol. 1. Ch. 20. Hoboken, NJ: Wiley; 2003. p. 847-900.
3. Palleti DJ, Chitti S, Babu PA. Virtual screening and molecular docking analysis of Zap - 70 kinase inhibitors. Int J Chem Anal Sci 2011;2(9):1208-11.
4. Morris GM, Lim-Wilby M. Molecular docking. Methods Mol Biol 2008;443:365-82.
5. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46(1-3):3-26.
6. Welsh GI, Proud CG. Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. Biochem J 1993;294:625-9.
7. Phukan S, Babu VS, Kannoji A, Hariharan R, Balaji VN. GSK3beta: Role in therapeutic landscape and development of modulators. Br J Pharmacol 2010;160(1):1-19.
8. Uciechowska U, Schemies J, Scharfe M, Lawson M, Wichapong K, Jung M, et al. Binding free energy calculations and biological testing of novel thiobarbiturates as inhibitors of the human NAD+ dependent histone deacetylase Sirt2. Med Chem Commun 2012;3(2):167-73.
9. Pouplana R, Lozano JJ, Ruiz J. Molecular modelling of the differential interaction between several non-steroidal anti-inflammatory drugs and human prostaglandin endoperoxide H synthase-2 (h-PGHS-2). J Mol Graph Model 2002;20(4):329-43.
Statistics
547 Views | 616 Downloads
Citations
How to Cite
Varadharaj, V., and N. Kandakatl. “GLYCOGEN SYNTHASE KINASE-3 BETA PROTEIN INHIBITION BY SELECTED PHYTOCOMPOUNDS IN SILICO”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, no. 1, Jan. 2017, pp. 87-90, doi:10.22159/ajpcr.2017.v10i1.14113.
Section
Original Article(s)